Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells

• Published in: Cancer chemotherapy and pharmacology Vol. 63; no. 6; pp. 1023 - 1033
• Main Authors: Queiroz, Alexandre F. S, Silva, Rodrigo A, Moura, Raniere M, Dreyfuss, Juliana L, Paredes-Gamero, Edgar J, Souza, Ana C. S, Tersariol, Ivarne L. S, Santos, Elizeu A, Nader, Helena B, Justo, Giselle Z, de Sales, Maurício P
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Berlin/Heidelberg : Springer-Verlag 01.05.2009; Springer-Verlag; Springer; Springer Nature B.V
• Subjects: Animals; Antineoplastic agents; Antineoplastic Agents - isolation & purification; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Biological and medical sciences; Cancer Research; Caspases - metabolism; Cell Culture Techniques; Cell Proliferation - drug effects; Cell Survival - drug effects; Cliona; Clione - chemistry; Flow Cytometry; Hematologic and hematopoietic diseases; Humans; Immunoblotting; Inhibitory Concentration 50; Jurkat Cells; K562 Cells; Lectins - isolation & purification; Lectins - pharmacology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphocytes - cytology; Lymphocytes - drug effects; Medical sciences; Medicine; Medicine & Public Health; Oncology; Original Article; Pharmacology. Drug treatments; Pharmacology/Toxicology; Cathepsin B; Lectin; Cytotoxicity; K562; Antitumor; Apoptosis; Antineoplastic agent; Erythroleukemia; Human; Enzyme; Growth; Cysteine endopeptidases; Acute; Malignant hemopathy; In vitro; Biological activity; Peptidases; Myeloproliferative syndrome; M6 acute myelocytic leukemia; Cell death; Established cell line; Hydrolases; Cell; Cancer; Lectin; Cliona varians; K562
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-008-0825-4

Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.